相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Acquired Resistance to Immune Checkpoint Inhibitors
Adam J. Schoenfeld et al.
CANCER CELL (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice
Liang Wen et al.
HEPATOLOGY (2019)
Combined locoregional-immunotherapy for liver cancer
Tim F. Greten et al.
JOURNAL OF HEPATOLOGY (2019)
Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention
Mengxin Tian et al.
SCIENCE CHINA-LIFE SCIENCES (2019)
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta et al.
CANCER DISCOVERY (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
A tumorigenic index for quantitative analysis of liver cancer initiation and progression
Gaowei Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
The immunology of hepatocellular carcinoma
Marc Ringelhan et al.
NATURE IMMUNOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
42,573 cases of hepatectomy in China: a multicenter retrospective investigation
Binhao Zhang et al.
SCIENCE CHINA-LIFE SCIENCES (2018)
Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
Adam Nagy et al.
SCIENTIFIC REPORTS (2018)
Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma
Otilia Menyhart et al.
ROYAL SOCIETY OPEN SCIENCE (2018)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang et al.
ANNALS OF ONCOLOGY (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions
Jin Lee et al.
CELL REPORTS (2017)
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma
Jittiporn Chaisaingmongkol et al.
CANCER CELL (2017)
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Chunhong Zheng et al.
CELL (2017)
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer
A. Blythe Ryerson et al.
CANCER (2016)
Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells
Xiaolin Luo et al.
CELL REPORTS (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
The yin and yang of evasion and immune activation in HCC
Oxana V. Makarova-Rusher et al.
JOURNAL OF HEPATOLOGY (2015)
Immunological landscape and immunotherapy of hepatocellular carcinoma
Jesus Prieto et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
Combinatorial Immunotherapy of Polyinosinic-Polycytidylic Acid and Blockade of Programmed Death-Ligand 1 Induce Effective CD8 T-cell Responses against Established Tumors
Toshihiro Nagato et al.
CLINICAL CANCER RESEARCH (2014)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions
Tai Hato et al.
HEPATOLOGY (2014)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2013)
Conflicting Roles of Molecules in Hepatocarcinogenesis: Paradigm or Paradox
Gen-Sheng Feng
CANCER CELL (2012)
Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice
Bastian Hoechst et al.
HEPATOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Liver: An organ with predominant innate immunity
Bin Gao et al.
HEPATOLOGY (2008)
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma
F Korangy et al.
CLINICAL CANCER RESEARCH (2004)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance
A Limmer et al.
NATURE MEDICINE (2000)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
